Psyched Wellness Adds Amanita Muscaria Expert To Advisory Board

Kevin Feeney has joined the advisory board of that of Psyched Wellness (CSE: PSYC) as of this morning. Feeney will be working with the company to identify novel uses for the psychoactive constituent in Amanita Muscaria, which is known as Muscimol.

Feeny is a cultural anthropologist and lawyer, whom current serves as program director as well as an instructor in interdisciplinary studies – social sciences at the Central Washington University. Viewed as an expert on the Amanita muscaria mushroom, his primary research is focused on examining legal and regulatory issues that surround psychoactive substances, as well as exploring both the modern and traditional uses of these unique species of mushrooms.

Furthermore, Feeney, whom has a PhD in cultural anthropology, has many publications to his name, including an edited volume on amanita muscaria within Fly Agaric: A Compendium of History, Pharmacology, Mythology, and Exploration, while having also been published in the Journal of Psychoactive Drugs and the International Journal of Drug Policy among others.

Commenting on his appointed as scientific advisor to Psyched Wellness, Feeney stated, “Amanita Muscaria has a long history of use for treating a number of ailments including anxiety, insomnia, pain, and inflammation. While this mushroom has been largely overlooked in both standard and alternative medicines, its potential applications are rich and largely unexplored, and shows promise in such disparate areas as treating alcohol and benzodiazepine withdrawal as well as alleviating cognitive impairments related to Lyme disease and Alzheimer’s.”

The addition to the board of advisors is seen as being a key development within the growth of the company. The experience brought forth by Feeny is expected to assist the company in identifying new novel uses of the compound, in applications for health and wellness.

Psyched Wellness last traded at $0.195 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

How to Still Find 10-Bagger Gold and Silver Stocks | Don Durrett

First Majestic Silver: Jerritt Canyon Is BACK!

Canada May Finally Be Backing Its Battery Supply Chain | John Passalacqua – First Phosphate

Recommended

Kirkland Lake Discoveries Drills 39.35 g/t Gold Over 16.4 Metres As Mirado Continues To Grow

Antimony Resources Expands Footprint as Soil Sampling Lights Up Ground South of Bald Hill

Related News

Psyched Wellness To Conduct Stability Tests On Proprietary Mushroom Extract

Psyched Wellness (CSE: PSYC) is progressing with the development of its flagship product, an extract...

Monday, July 26, 2021, 09:28:00 AM

Psyched Wellness Sees Positive Initial Results From AME-1 Extract Study

Psyched Wellness (CSE: PSYC) this morning provided an update on its study to determine the...

Thursday, February 4, 2021, 07:33:40 AM

Psyched Wellness Announces Study On Muscimol Antioxidant and Anti-Inflammatory Properties

Psyched Wellness (CSE: PSYC) has begun yet another study related to that of the Amanita...

Wednesday, January 6, 2021, 07:48:08 AM

Compass Pathways Leader Of Investment Climate For Psychedelic Plays – The Daily Dive feat Jeff Stevens

Today on the Daily Dive, Jeff Stevens returns to the show to sit down with...

Wednesday, December 30, 2020, 01:30:00 PM

Psyched Wellness Increases Bought Deal To $5.5 Million

Psyched Wellness (CSE: PSYC) has increased the size of its bought deal private placement as...

Monday, January 25, 2021, 07:09:05 AM